- Home
- MVIS vs TNGX Comparison
MVIS vs TNGX Comparison
Compare MVIS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- TNGX
- Stock Information
- Founded
- MVIS 1993
- TNGX 2014
- Country
- MVIS United States
- TNGX United States
- Employees
- MVIS N/A
- TNGX N/A
- Industry
- MVIS Industrial Machinery/Components
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MVIS Technology
- TNGX Health Care
- Exchange
- MVIS Nasdaq
- TNGX Nasdaq
- Market Cap
- MVIS 281.7M
- TNGX 351.2M
- IPO Year
- MVIS 1996
- TNGX N/A
- Fundamental
- Price
- MVIS $1.16
- TNGX $6.01
- Analyst Decision
- MVIS Buy
- TNGX Strong Buy
- Analyst Count
- MVIS 4
- TNGX 6
- Target Price
- MVIS $2.50
- TNGX $12.20
- AVG Volume (30 Days)
- MVIS 7.7M
- TNGX 2.7M
- Earning Date
- MVIS 08-06-2025
- TNGX 08-06-2025
- Dividend Yield
- MVIS N/A
- TNGX N/A
- EPS Growth
- MVIS N/A
- TNGX N/A
- EPS
- MVIS N/A
- TNGX N/A
- Revenue
- MVIS $4,329,000.00
- TNGX $40,990,000.00
- Revenue This Year
- MVIS $508.18
- TNGX N/A
- Revenue Next Year
- MVIS $86.32
- TNGX N/A
- P/E Ratio
- MVIS N/A
- TNGX N/A
- Revenue Growth
- MVIS N/A
- TNGX 10.09
- 52 Week Low
- MVIS $0.80
- TNGX $1.03
- 52 Week High
- MVIS $1.95
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MVIS 53.57
- TNGX 76.36
- Support Level
- MVIS $1.10
- TNGX $5.34
- Resistance Level
- MVIS $1.19
- TNGX $6.40
- Average True Range (ATR)
- MVIS 0.07
- TNGX 0.50
- MACD
- MVIS 0.01
- TNGX -0.02
- Stochastic Oscillator
- MVIS 65.45
- TNGX 84.08
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.